Department of Biomedical Technologies

It has been established that, under in vitro conditions, the developed bioactive bioplastic material prevents the death of fibroblasts and stimulates their proliferative activity under conditions simulating acute and chronic inflammation. It was revealed that the manufactured bioactive bioplastic material, under in vitro conditions, prevents spontaneous activation of human blood monocytes, inhibits their differentiation into the pro-inflammatory M1 phenotype and promotes the transition of monocytes to the pro-regenerative M2 phenotype. Under in vivo conditions, it was shown that a bioactive bioplastic material promotes the restoration of the skin in experimental rats after thermal damage. At the same time, the clinical effectiveness of the bioplastic material is superior to therapy using Levomekol ointment. A technology has been developed for integrating the components of a bioactive bioplastic material with a synthetic polymer material. The resulting hybrid material, both in vitro and in vivo, has an anti-inflammatory and pro-regenerative effect, and is also characterized by improved gas permeability, strength and elasticity.